Uxin Ltd: Form 20-F for the period ended Dec 31, 2025
Filed with the SEC on Apr 30, 2026 and accepted by EDGAR at Apr 30, 2026, 16:06 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2025-01-01 to 2025-12-31 | $463.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2025-01-01 to 2025-12-31 | $432.3m | us-gaap:CostOfRevenue |
| Gross profit | 12 months2025-01-01 to 2025-12-31 | $30.9m | us-gaap:GrossProfit |
| Research and development | 12 months2025-01-01 to 2025-12-31 | $1.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2025-01-01 to 2025-12-31 | −$24.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2025-01-01 to 2025-12-31 | $13.5m | us-gaap:InterestExpense |
| Income tax | 12 months2025-01-01 to 2025-12-31 | $6.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2025-01-01 to 2025-12-31 | −$37.5m | us-gaap:ProfitLoss |
| Diluted EPS | 12 months2025-01-01 to 2025-12-31 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2025-01-01 to 2025-12-31 | $0.00 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2025-01-01 to 2025-12-31 | 62,756,316,162 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2025-01-01 to 2025-12-31 | −$72.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2025-01-01 to 2025-12-31 | $3.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-12-31 | $11.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-12-31 | $106.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-12-31 | $345.9m | us-gaap:Assets |
| Current liabilities | At period end2025-12-31 | $139.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-12-31 | $330.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-12-31 | −$33.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-26-020425. Last ingested by Listed: Nov 13, 2026, 15:00 ET. Listed shows no prices and gives no investment advice.